logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
delete
arrow
返回
M

Markus Hinder

novartis

23H指数
84论文数
1.7K被引数
收录论文 42
发表时间
logo
Reassessing R&D outcomes of leading pharmaceutical companies重新评估领先制药公司的研发成果
errDrug Discovery Today
IF7.5
err2026-08-11
err0
errOAAI
errAlexander Schuhmacher; Michael Witting; Dominik Hartl; Markus Hinder; Oliver Gassmann
err分享
err收藏
Letter to the Editor of the British Journal of Clinical Pharmacology Re: van Iersel et al. (2026)—Why do healthy volunteers participate in clinical trials? doi: https://doi.org/10.1002/bcp.70499致《英国临床药理学杂志》编辑的信：van Iersel et al. (2026)—为何健康志愿者参与临床试验？doi: https://doi.org/10.1002/bcp.70499
errBritish Journal of Clinical Pharmacology
IF3
err2026-05-10
err0
PREAI
errKasra Shakeri-Nejad; Markus Hinder
err分享
err收藏
New perspectives for better R&D performance: lessons learned from leading pharma companies提升研发绩效的新视角：来自领先制药公司的经验教训
errDrug Discovery Today
IF7.5
err2026-04-17
err0
errOAAI
errAlexander Schuhmacher; Oliver Gassmann; Sara Knapp; Dominik Hartl; Markus Hinder
err分享
err收藏
A Phase 2 (2a) Randomized Trial of Iscalimab in Adolescents and Young Adults with New-Onset Type 1 Diabetes一项关于Iscalimab在青少年和新发1型糖尿病青年患者中的2期（2a）随机试验
errDIABETES TECHNOLOGY & THERAPEUTICS
IF6.3
err2025-11-01
err0
errOAAI
errMathieu, Chantal; Quinlan, Michelle; Wagner, Kristina; Kompa, Jill; Hartmann, Nicole; Hughes, Maria F.; Hinder, Markus; O'Donnell, Christopher J.; Goldfine, Allison B.
err分享
err收藏
The R&D productivity challenge: transforming the pharmaceutical ecosystem研发生产力挑战：变革制药生态系统
errDrug Discovery Today
IF7.5
err2025-10-09
err0
errOAAI
errAlexander Schuhmacher; Oliver Gassmann; Sebastian Kwisda; Malte Kremer; Markus Hinder; Dominik Hartl
err分享
err收藏
The Role of Data Monitoring Committees in drug research数据监查委员会在药物研究中的作用
errDrug Discovery Today
IF7.5
err2025-09-18
err0
PREAI
errMarkus Hinder; Nandhini Madesh; Dominik Hartl; Alexander Schuhmacher
err分享
err收藏
Letter to the editor of the Brit J Clin Pharmacol on Heuberger et al. 2025 https://doi.org/10.1002/bcp.70090致《Brit J Clin Pharmacol》编辑的一封信，关于Heuberger et al. 2025（https://doi.org/10.1002/bcp.70090）
errBritish Journal of Clinical Pharmacology
IF3
err2025-06-20
err0
PREAI
errMarkus Hinder; Vikram P. Sinha
err分享
err收藏
Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022) (vol 30, 104291, 2025)对领先制药公司研发成功率进行基准测试：一项关于FDA批准（2006-2022年）的实证分析（卷30，104291，2025）
errDRUG DISCOVERY TODAY
IF7.5
err2025-05-01
err0
PREAI
errSchuhmacher, Alexander; Hinder, Markus; Brief, Elazar; Gassmann, Oliver; Hartl, Dominik
err分享
err收藏
A case study assessing the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companies
errDRUG DISCOVERY TODAY
IF7.5
err2025-03-01
err0
errOAAI
errSchuhmacher, Alexander; Grinchenko, Kyrylo; Gassmann, Oliver; Hartl, Dominik; Hinder, Markus
err分享
err收藏
Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022)
errDRUG DISCOVERY TODAY
IF7.5
err2025-02-01
err0
errOAAI
errSchuhmacher, Alexander; Hinder, Markus; Brief, Elazar; Gassmann, Oliver; Hartl, Dominik
err分享
err收藏
Comparative analysis of FDA approvals by top 20 pharma companies (2014-2023)前20家制药公司FDA批准的比较分析 (2014-2023)
errDRUG DISCOVERY TODAY
IF7.5
err2024-09-01
err2
errOAAI
errSchuhmacher, Alexander; Gassmann, Oliver; Hinder, Markus; Hartl, Dominik
err分享
err收藏
Is the blockbuster imperative broken
errDRUG DISCOVERY TODAY
IF7.5
err2023-11-01
err1
PREAI
errSchuhmacher, Alexander; Hinder, Markus; Boger, Nikolaj; Gassmann, Oliver; Hartl, Dominik
err分享
err收藏
Analysis of pharma R&D productivity - a new perspective needed制药研发生产率分析 -- 需要一个新的视角
errDRUG DISCOVERY TODAY
IF7.5
err2023-10-01
err26
PREAI
errSchuhmacher, Alexander; Hinder, Markus; Stein, Alexander von Stegmann und; Hartl, Dominik; Gassmann, Oliver
err分享
err收藏
Investigating the origins of recent pharmaceutical innovation
errNATURE REVIEWS DRUG DISCOVERY
IF101.8
err2023-07-05
err9
PREAI
errSchuhmacher, Alexander; Hinder, Markus; Dodel, Alexander; Gassmann, Oliver; Hartl, Dominik
err分享
err收藏
The significance of blockbusters in the pharmaceutical industry
errNATURE REVIEWS DRUG DISCOVERY
IF101.8
err2022-12-12
err9
PREAI
errSchuhmacher, Alexander; Hinder, Markus; Boger, Nikolaj; Hartl, Dominik; Gassmann, Oliver
err分享
err收藏
Open innovation: A paradigm shift in pharma R&D?
errDRUG DISCOVERY TODAY
IF7.5
err2022-09-01
err24
PREAI
errSchuhmacher, Alexander; Gassmann, Oliver; Bieniok, Doria; Hinder, Markus; Hartl, Dominik
err分享
err收藏
Systematic risk identification and assessment using a new risk map in pharmaceutical R&D
errDRUG DISCOVERY TODAY
IF7.5
err2021-12-01
err7
PREAI
errSchuhmacher, Alexander; Brieke, Clara; Gassmann, Oliver; Hinder, Markus; Hartl, Dominik
err分享
err收藏
Big Techs and startups in pharmaceutical R&D - A 2020 perspective on artificial intelligence医药研发领域的大科技与初创企业 -- 人工智能的2020视角
errDRUG DISCOVERY TODAY
IF7.5
err2021-10-01
err12
PREAI
errSchuhmacher, Alexander; Gatto, Alexander; Kuss, Michael; Gassmann, Oliver; Hinder, Markus
err分享
err收藏
A framework to guide dose & regimen strategy for clinical drug development
errCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY
IF3
err2021-09-25
err9
errOAAI
errSander, Oliver; Magnusson, Baldur; Ludwig, Inga; Jullion, Astrid; Meille, Christophe; Lorand, Daniel; Bornkamp, Bjoern; Hinder, Markus; Kovacs, Steven J.; Looby, Michael
err分享
err收藏
LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest HypertriglyceridemiaLLF580，一种FGF21类似物，可降低中度高甘油三酯血症肥胖成人的甘油三酯和肝脂肪
errJOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
IF5.1
err2021-08-25
err33
errOAAI
errRader, Daniel J.; Maratos-Flier, Eleftheria; Nguyen, Amanda; Hom, Doug; Ferriere, Michael; Li, Yifang; Kompa, Jill; Martic, Miljen; Hinder, Markus; Basson, Craig T.; Yowe, David; Diener, John; Goldfine, Allison B.; Bajaj, Archna; Escalon, Maricer; Fein, Melanie; Hunt, Allen; Kankam, Martin K.; Koren, Michael; Smith, William; Wilson, Jessica
err分享
err收藏

研究方向

暂时未获取到该数据
合作学者
合作期刊
D
Daniel J. Rader
H 指数: 172 · 论文数: 1.5K
C
Christopher J. O’Donnell
H 指数: 155 · 论文数: 795
D
David E. Newby
H 指数: 132 · 论文数: 1.6K
C
Colin Berry
H 指数: 109 · 论文数: 1.3K
R
Richard W. Siegel
H 指数: 81 · 论文数: 382
查看更多